{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464213473
| IUPAC_name = [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2-furyl)methanone
| image = Prazosin Structure V.1.svg
| width = 240px
<!--Clinical data-->
| Drugs.com = {{drugs.com|monograph|prazosin-hydrochloride}}
| MedlinePlus = a682245
| pregnancy_category =  
| legal_UK = POM
| legal_US = Rx only
| licence_US = Prazosin
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = ~60%
| protein_bound = 97%
| metabolism =  
| elimination_half-life = 2–3 hours
| onset = 30–90&nbsp;minutes<ref name="pmid761333">{{cite journal | vauthors = Packer M, Meller J, Gorlin R, Herman MV | title = Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure | journal = Circulation | volume = 59 | issue = 3 | pages = 531–9 | year = 1979 | pmid = 761333 | doi = 10.1161/01.cir.59.3.531| url = }}</ref>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 19216-56-9
| ATC_prefix = C02
| ATC_suffix = CA01
| ATC_supplemental =  
| PubChem = 4893
| IUPHAR_ligand = 503
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00457
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4724
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XM03YJ541D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08411
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8364
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 2
<!--Chemical data-->
| C=19 | H=21 | N=5 | O=4
| molecular_weight = 383.401 g/mol
| smiles = O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)c4occc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IENZQIKPVFGBNW-UHFFFAOYSA-N
}}

'''Prazosin''', trade names '''Minipress''', '''Vasoflex''', '''Lentopres''' and '''Hypovase''', is a [[sympatholytic]] drug used to treat [[hypertension|high blood pressure]], [[anxiety]], and [[posttraumatic stress disorder]] (PTSD).<ref name="Minipress Rx Info">{{cite web|title=Minipress Prescribing Information|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017442%20s043lbl.pdf|website=United States Food and Drug Administration|publisher=Pfizer|accessdate=3 June 2016|date=February 2015}}</ref><ref name="Prazosin clinical data">{{cite web|title=Prazosin: Clinical data|url=http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=503|website=IUPHAR|publisher=International Union of Basic and Clinical Pharmacology|accessdate=3 June 2016 | quote = This sympatholytic drug is used in the treatment of hypertension, anxiety and post-traumatic stress disorder.&nbsp;... Antagonist of alpha-1 adrenoceptors on vascular smooth muscle, thereby inhibiting the vasoconstrictor effect of circulating and locally-released adrenaline and noradrenaline, resulting in peripheral vasodilation.}}</ref> It is an [[Alpha-1 blocker|&alpha;<sub>1</sub>-blocker]] which acts as an [[inverse agonist]] at [[alpha-1 adrenergic receptor]]s.<ref name="Prazosin biological activity">{{cite web|title=Prazosin: Biological activity|url=http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=503|website=IUPHAR|publisher=International Union of Basic and Clinical Pharmacology|accessdate=3 June 2016}}</ref>  These receptors are found on [[vascular smooth muscle]], where they are responsible for the [[vasoconstrictive]] action of [[norepinephrine]].<ref name="Prazosin clinical data" />  They are also found throughout the [[central nervous system]].<ref name="pmid9285356">{{Cite journal | doi = 10.1016/S0891-0618(97)00042-2 | last1 = Day | first1 = H. E. | last2 = Campeau | first2 = S. | last3 = Watson Jr | first3 = S. J. | last4 = Akil | first4 = H. | title = Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord | journal = Journal of chemical neuroanatomy | volume = 13 | issue = 2 | pages = 115–139 | year = 1997 | pmid = 9285356}}</ref> As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.

==Medical use==
Prazosin is orally active and has a minimal effect on cardiac function due to its [[alpha-1 receptor]] selectivity. However, when prazosin is started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached [[homeostasis]] at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.

The antihypertensive characteristics of prazosin make it a second-line choice for the treatment of high blood pressure.<ref name=pharmnemonics>{{Cite book | author=Shen, Howard | title=Illustrated Pharmacology Memory Cards: PharMnemonics | year=2008 | publisher=Minireview | isbn=1-59541-101-1 | page=13}}</ref>

Prazosin is also useful in treating urinary hesitancy associated with [[benign prostatic hyperplasia|prostatic hyperplasia]], blocking alpha-1 receptors, which control constriction of both the [[prostate]] and [[urethra]]. Although not a first line choice for either hypertension or prostatic hyperplasia, it is a choice for patients who present with both problems concomitantly.<ref name=pharmnemonics />

There is some evidence that this medication is effective in treating nightmares, mixed results in randomized control trials.<ref name=kung12>{{ cite journal | journal = Mayo Clin Proc. |year= 2012 |volume= 87 |issue=9 |pages= 890–900 |doi= 10.1016/j.mayocp.2012.05.015 |pmc= 3538493 |title= Treatment of Nightmares With Prazosin: A Systematic Review |author= Kung S, Espinel Z, Lapid MI }}</ref>

The drug is usually recommended for severe stings from Indian Red Scorpion ''[[Hottentotta tamulus]]'' in Indian Subcontinent.<ref name="bawaskar&bawaskar2008">{{cite journal|year=2008|title=Scorpion sting: A study of clinical manifestations and treatment regimes|url=http://www.currentscience.ac.in/Downloads/article_id_095_09_1337_1341_0.pdf|format=[[Portable Document Format|PDF]]|journal=[[Current Science]]|volume=95|issue=9|pages=1337–1341|author1=Bawaskar, H.S.  |author2=P.H. Bawaskar |lastauthoramp=yes |accessdate=14 April 2010}}</ref><ref name=bawaskar&bawaskar2007>{{cite journal |author1=Bawaskar, H.S.  |author2=P.H. Bawaskar  |lastauthoramp=yes |year=2007 |title=Utility of scorpion anti-venin vs. prazosin in the management of severe ''Mesobuthus tamulus'' (Indian red scorpion) envenoming at rural settings |journal=[[JAPI]] |volume=55 |pages=14–21|url=http://www.japi.org/january2007/O-14.pdf|format=[[Portable Document Format|PDF]] |accessdate=14 April 2010}}</ref><ref>{{cite journal|last1=Pandi|first1=K.|last2=Krishnamurthy|first2=S.|last3=Srinivasaraghavan|first3=R.|last4=Mahadevan|first4=S.|title=Efficacy of scorpion antivenom plus prazosin versus prazosin alone for Mesobuthus tamulus scorpion sting envenomation in children: a randomised controlled trial|journal=Archives of Disease in Childhood|date=18 February 2014|volume=99|issue=6|pages=575–580|doi=10.1136/archdischild-2013-305483|pmid=24550184}}</ref>

==Adverse effects==

Common (4–10% frequency) side effects of prazosin include [[dizziness]], headache, [[drowsiness]], lack of energy, weakness, [[palpitations]], and nausea.<ref name="Minipress Rx Info" /> Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, [[edema]], [[orthostatic hypotension]], [[dyspnea]], [[Syncope (medicine)|syncope]], [[vertigo]], depression, nervousness, and rash.<ref name="Minipress Rx Info" /> A very rare side effect of prazosin is [[priapism]].<ref name="Minipress Rx Info" /><ref name="pmid519276">{{cite journal |vauthors=Bhalla AK, Hoffbrand BI, Phatak PS, Reuben SR |title=Prazosin and priapism |journal=Br Med J |volume=2 |issue=6197 |pages=1039 |date=October 1979 |pmid=519276 |pmc=1596841 |doi= 10.1136/bmj.2.6197.1039|url=}}</ref> One phenomenon associated with prazosin is known as the "[[first dose response]]", in which the side effects of the drug{{snd}} specifically orthostatic hypotension, dizziness, and drowsiness{{snd}} are especially pronounced in the first dose.<ref name="Minipress Rx Info" />

Orthostatic hypotension and syncope are associated with the body's poor ability to control blood pressure without active alpha-adrenergic receptors. Patients on prazosin should be told to rise to stand up slowly, since their poor baroreflex may cause them to faint if their blood pressure is not adequately maintained during standing. The nasal congestion is due to dilation of vessels in the nasal [[mucosa]].

==Research==
Prazosin holds promise as a pharmacologic treatment for alcohol dependence after a 2009 pilot trial<ref>{{cite journal |pmid=18945226 |year=2009 |last1=Simpson |first1=TL |last2=Saxon |first2=AJ |last3=Meredith |first3=CW |last4=Malte |first4=CA |last5=McBride |first5=B |last6=Ferguson |first6=LC |last7=Gross |first7=CA |last8=Hart |first8=KL |last9=Raskind |first9=M |title=A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence |volume=33 |issue=2 |pages=255–63 |doi=10.1111/j.1530-0277.2008.00807.x |journal=Alcoholism: Clinical and Experimental Research|url=https://zenodo.org/record/853433 }}</ref> was completed. A larger controlled Phase II "Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence" is currently underway.<ref>[http://clinicaltrials.gov/ct2/show/NCT00762710 Study of the Medication Prazosin for Alcohol Dependence]</ref>

In cancer research, Prazosin triggered [[apoptosis]] of [[glioblastoma]]‐initiating cells and of their differentiated progeny, inhibited glioblastoma growth in [[Patient-derived tumor xenograft|orthotopic xenografts of patient‐derived glioblastoma‐initiating cells]], and increased survival of glioblastoma‐bearing mice. Its activity occurred via a [[PRKCD|PKCδ]]‐dependent inhibition of the [[Protein kinase B|AKT]] pathway, which resulted in [[Caspase 3|caspase‐3]] activation. So, prazosin is a potential anti‐glioblastoma adjuvant drug.<ref>S. Assad Kahn, S. L. Costa, S. Gholamin, R. T. Nitta, L. G. Dubois, M. Feve, M. Zeniou, P. L. C. Coelho, E. El-Habr, J. Cadusseau, P. Varlet, S. S. Mitra, B. Devaux, M.-C. Kilhoffer, S. H. Cheshier, V. Moura-Neto, J. Haiech, M.-P. Junier, H. Chneiweiss. (2016). The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKC -dependent inhibition of the AKT pathway. EMBO Molecular Medicine,  {{DOI|10.15252/emmm.201505421}}</ref> Clinical trials will be initiated to confirm these findings. Understanding the mechanism of action of prazosin may pave the way for the development of new potential treatments also for other cancers, since other cancer cells as well display altered PKCδ signaling, including those in colorectal, pancreatic and liver cancer.<ref>[https://www.sciencedaily.com/releases/2016/04/160421085706.htm  Recycling an anti-hypertensive agent to fight brain tumors]. ScienceDaily 21 April 2016</ref>

==References==
{{Reflist|2}}

{{Antihypertensives and diuretics}}
{{Anxiolytics}}
{{Adrenergics}}
{{Peripheral vasodilators}}

[[Category:Alpha-1 blockers]]
[[Category:Furans]]
[[Category:Quinazolines]]
[[Category:Antihypertensive agents]]
[[Category:Anxiolytics]]
[[Category:Piperazines]]
[[Category:Carboxamides]]
[[Category:Phenol ethers]]
[[Category:Vasodilators]]